

## DAFTAR PUSTAKA

1. Jiang S, Shan F, Zhang Y, Jiang L dan Chang Z. Increase serum IL-17 and decrease serum IL-10 and IL-35 levels correlate with the progression of COPD. *International Journal of COPD*, 2018 ; 13 : 2483-2494
2. Silva BSA, Lira FS, Ramos D, Uzeloto JS, Rossi FE, Freire AP, et al. Severity of COPD and its relationship with IL-10. *Cytokine*, 2018 Jun ; 106 : 95-100
3. GOLD Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2019; diakses dari [www.goldcopd.org](http://www.goldcopd.org)
4. Barnes PJ. Inflammatory mechanisms in patient with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*, 2016 ; 138 : 16-27
5. Laniado-Laborin R. Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel epidemics of the 21th century. *Int.J. Environ. Res. Public Health*, 2009; 6: 209-224
6. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol*, 2009; 41 : 631-638
7. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. *Cytokine Growth Factor Rev*. 2010 Oct; 21(5) :331-44. Doi:10.1016/j.cytogfr.2010.09.002
8. Ogawa Y, Duru EA, dan Ameredes T. Role of IL-10 in the resolution of airway inflammation. *Current Molecular Medicine*, 2008 ; 8 : 437-445
9. Ouyang W, Rutz S, Crellin NK, Valdez PA, dan Hymowitz SG. Regulation and Functions of the IL-10 family of cytokines in inflammation and disease. *Annu. Rev. Immunol*. 2011; 29: 71-109
10. Raheerison C dan Girodet PO. Epidemiology of COPD review. *Eur Respir Rev*, 2009, 18;114 : 213-221
11. Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease : a literature review. *International Journal of COPD*, 2012 ; 7 : 457-494
12. Huang AX, Lu LW, Liu WJ, dan Huang M. Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF- $\alpha$  levels correlate with pulmonary function in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome. *Med Sci Monit*, 2016 ; 22 : 2800-2808
13. Takanashi S, Hasegawa Y, Kanehira K, Yamamoto K, Fujimoto K, Satoh K, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. *Eur Respir J*, 1999 ; 14 : 309-314
14. Perhimpunan Dokter Paru Indonesia. PPOK (Penyakit Paru Obstruktif Kronik), Diagnosis dan penatalaksanaan. Amin M, Yunus F, Antariksa B,

- Djajalaksana S, Wiyono WH, Sutoyo DK, et al. (editor). Jakarta, *UI-Press*, 2016
15. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest*, 2008; 118 (11) : 3546-3556
  16. Barnes PJ dan Rennard SI. Pathophysiology of COPD. Dalam : Barnes PJ, Drazen J, Rennard SI dan Thomson N (editor) *Asthma and COPD, Basic Mechanisms and Clinical Management edisi ke-2.. San Diego : Academic Press*. 2009. Hal. 425-442
  17. MacNee W. ABC of chronic obstructive pulmonary disease. Pathology, pathogenesis, and pathophysiology. *BMJ*, 2006; 332: 1202-4
  18. Johns DP, Walters JAE dan Walters EH. Diagnosis and early detection of COPD using spirometry. *J Thorac Dis*, 2014; 6 (11) : 1557-1569
  19. Tennesen P. Smoking cessation and COPD, clinical year in review. *Eur Respir Rev*, 2013; 22(127) : 37-43
  20. Cheng SL, Lin CH, Wang CC, Chan MC, Hsu JY, Hang LW, dkk. Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients. *Journal of the Formosan Medical Association*, 2019 Jan; 118 (1 Pt 3) : 429-435
  21. Pires N, Pinto P, Marcal N, Ferreira AJ, Rodrigues C, dan Barbara C. Pharmacological treatment of COPD – New evidence, review. *Pulmonol*, 2019; 25(2) : 90-96
  22. LeVan TD, Romberger DJ, Siahpus M, Grimm BL, Ramos AK, Johansson PL, dkk. Relationship of systemic IL-10 levels with proinflammatory cytokine responsiveness and lung function in agriculture workers. *Respiratory Research*, 2018; 19:166
  23. Armstrong L, Jordan N, Millar A. Interleukin 10 (IL-10) regulation of tumor necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes. *Thorax*, 1996 Feb; 51(2): 143-149
  24. Beamer GL, Flaherty DK, Assogba BD, Stromberg P, Gonzalez-Juarrero M, Malefyt R, dkk. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J Mice. *J Immunol*. 2008 October 15; 181(8): 5545-5550
  25. Van Keulen HV, Gomes AS, Toffolo MCF, Oliveira EE, et al. Serum levels of nitric oxide and cytokines in smokers at the beginning and after 4 months of treatment for smoking cessation. *International Journal of Cardiology*, 2017; 230: 327-331
  26. Zhang L, Cheng Z, Liu W dan Wu K. Expression of Interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. *COPD*, 2013;10:459-465

27. Zhao S, Wu D, Wu P, Wang Z, dan Huang J. Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis. *PLoS ONE*. 2015; 10 (10): e0139598
28. Ndishimye P, Seghrouchni F, Domokos B, Soritau O, Sadak A, Homorodean D, dkk. Evaluation of Interleukin-10 levels in the plasma of patients with various stages of tuberculosis. *Clujul Medical*. 2015; 88 (2) : 164-167
29. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, dkk. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. *CHEST*. 2000; 117:365-373
30. Tian G, Li JL, Wang D, dan Zhou D. Targeting IL-10 in auto-immune diseases. *Cell Biochem Biophys*. 2014. DOI 10.1007/s 12013-014-9903-x
31. Borish L, Aarons A, Rumblyrt J, Cvietusa P, Negri J, dan Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. *J Allergy Clin Immunol*. 1996; 97:1288-96
32. Abd-Elaziz AA, Alwahsh RA, Abd-Elaal GA, dan Tameem AAM. Correlation between CAT score, inflammatory markers and pulmonary function tests in patient with acute exacerbation of COPD. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2017; 66: 243-246
33. Moore VC. Spirometry: step by step. *Breathe*. 2012; 8 (3): 233-240
34. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, dkk. General considerations for lung function testing. *Eur Respir J*. 2005 ; 26 : 153-161
35. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, dkk. Standardisation of spirometry. *Eur Respir J*. 2005 ; 26: 319-338
36. GINA Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019. Diakses dari [www.ginasthma.org](http://www.ginasthma.org)
37. Sastroasmoro S, dan Ismael S (editor). Dasar-Dasar Metodologi Penelitian Klinis edisi ke-5. Jakarta : *Sagung Seto*, 2016
38. Kleiner G, Marcuzzi A, Zanin V, Monasta L, dan Zauli G. Cytokine levels in the serum of healthy subjects. *Mediators Inflamm*. 2013; 2013:434010
39. Nussbaumer-Ochsner Y dan Rabe KF. Extrapulmonary effect of COPD. Dalam : Palange P dan Rohde G (editor) : ERS Handbook of Respiratory Medicine, 3<sup>rd</sup> edition. *The European Respiratory Society*, 2019, hal. 339-343
40. Sarkar M, Srinivasa, Madabkari I dan Kumar K. Tuberculosis associated chronic obstructive pulmonary disease. *Clin Respir J*. 2017 May; 11 (3) : 285-295
41. Lima VV, Zemse SM, Chiao CW, Bomfim GF, et al. Interleukin-10 limits increased blood pressure and vascular Rho-A/Rho-kinase signaling in angiotensin II-infused mice. *Life Sciences*, 2016; 145: 137-143
42. Odewusi OO dan Osadolor HB. Interleukin 10 and 18 levels in Essential Hypertensive. *J.Appl.Sci.EnvIRON.Manage*. 2019 May; 23(5): 819-824

43. Yaghini N, Mahmoodi M, Asadikaram GhR, Hassanskohi GhH et al. Serum levels of Interleukin 10 (IL-10) in patients with type 2 Diabetes. *Iran Red Crescent Med J*. 2011; 13(10) : 752
44. Namaei MH, Mortazavi-Moghaddan Sg, Eslami-Manoochehri R, Zardast M. The role of interleukin-10 dan 13 in tuberculosis-associated pulmonary dysfunction. *Caspian J Intern Med*, 2019; 10(2) : 223-227
45. Sarioglu N, Hismiogullasi AA, Bilen C, Erel F. Is the COPD assessment test (CAT) effective in demonstrating the systemic inflammation and other components in COPD? *Rev Post Pneumol*, 2016; 22(1) : 11-17
46. Kang HK, Kim K, Lee H, Jeong BH, Koh WJ, Park HY. COPD assessment test score and serum C-reactive protein levels in stable COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2016 Dec 8; 11: 3137-3143
47. Ghobadi H, Ahari SS, Kameli A, Lari SM. The relationship between COPD Assessment Test (CAT) scores and severity of airflow obstruction in stable COPD patients. *Tanaffos* 2012; 11(2): 22-26
48. Wei B dan Sheng Li C. Changes in Th1/Th2 producing cytokines during acute exacerbation chronic obstructive pulmonary disease. *Journal of International Medical Research*, 2018; 46(9) : 3890-3902
49. Braber S, Overbeek SA, Bezemer GFG, Henricks PA, et al. Smoking cessation reduces cytokine and chemokine levels but increases IL-10 in a mouse model for lung emphysema. *Am J Respir Crit Care Med* 181; 2010: A5061
50. Daloe MH, Mirhafez SR, Hasanian-Mohr M, Tajfard M, et al. Impact of cigarette smoking on serum pro- and anti-inflammatory cytokines and growth factors. *American Journal of Men's Health*. 2017; 11(4) : 1169-1173